Freedom Day Solutions LLC Decreases Position in Novo Nordisk A/S $NVO

by · The Cerbat Gem

Freedom Day Solutions LLC decreased its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,511 shares of the company’s stock after selling 555 shares during the period. Freedom Day Solutions LLC’s holdings in Novo Nordisk A/S were worth $1,554,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of NVO. Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth about $27,000. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth about $30,000. Disciplina Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the period. Finally, Spirit of America Management Corp NY acquired a new position in shares of Novo Nordisk A/S in the first quarter worth about $35,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. HSBC set a $70.00 price target on Novo Nordisk A/S in a research note on Wednesday, October 1st. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Finally, Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.50.

Read Our Latest Report on Novo Nordisk A/S

Novo Nordisk A/S Trading Down 1.6%

Shares of NYSE NVO opened at $58.64 on Friday. The stock’s 50 day moving average price is $55.26 and its two-hundred day moving average price is $63.33. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $120.56. The stock has a market capitalization of $261.83 billion, a P/E ratio of 16.11, a PEG ratio of 2.70 and a beta of 0.68. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Articles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).